Imunon (IMNN) Competitors

4.5% of Imunon shares are owned by institutional investors. 2.8% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Zhengye Biotechnology's return on equity of 0.00% beat Imunon's return on equity.

Zhengye Biotechnology has higher revenue and earnings than Imunon.

In the previous week, Zhengye Biotechnology and Zhengye Biotechnology both had 4 articles in the media. Zhengye Biotechnology's average media sentiment score of 1.17 beat Imunon's score of 0.22 indicating that Zhengye Biotechnology is being referred to more favorably in the media.

Zhengye Biotechnology has a beta of -2.18, suggesting that its share price is 318% less volatile than the broader market. Comparatively, Imunon has a beta of 1.96, suggesting that its share price is 96% more volatile than the broader market.

Imunon has a consensus target price of $10.00, indicating a potential upside of 414.14%. Given Imunon's stronger consensus rating and higher possible upside, analysts plainly believe Imunon is more favorable than Zhengye Biotechnology.

Actinium Pharmaceuticals' return on equity of -100.85% beat Imunon's return on equity.

Actinium Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 454.32%. Imunon has a consensus price target of $10.00, indicating a potential upside of 414.14%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Actinium Pharmaceuticals is more favorable than Imunon.

In the previous week, Imunon had 4 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 4 mentions for Imunon and 0 mentions for Actinium Pharmaceuticals. Imunon's average media sentiment score of 0.22 beat Actinium Pharmaceuticals' score of 0.00 indicating that Imunon is being referred to more favorably in the news media.

Imunon has lower revenue, but higher earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Actinium Pharmaceuticals has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market. Comparatively, Imunon has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market.

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 2.8% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Imunon had 3 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 4 mentions for Imunon and 1 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 1.89 beat Imunon's score of 0.22 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.

Imunon is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Comparatively, 2.8% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sensei Biotherapeutics has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market. Comparatively, Imunon has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market.

Sensei Biotherapeutics currently has a consensus price target of $58.50, indicating a potential upside of 73.72%. Imunon has a consensus price target of $10.00, indicating a potential upside of 414.14%. Given Imunon's higher probable upside, analysts clearly believe Imunon is more favorable than Sensei Biotherapeutics.

Sensei Biotherapeutics' return on equity of -83.59% beat Imunon's return on equity.

In the previous week, Imunon had 1 more articles in the media than Athira Pharma. MarketBeat recorded 4 mentions for Imunon and 3 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.93 beat Imunon's score of 0.22 indicating that Athira Pharma is being referred to more favorably in the media.

Athira Pharma is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 25.7% of Athira Pharma shares are held by insiders. Comparatively, 2.8% of Imunon shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Athira Pharma has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market. Comparatively, Imunon has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market.

Athira Pharma presently has a consensus price target of $15.00, suggesting a potential upside of 54.72%. Imunon has a consensus price target of $10.00, suggesting a potential upside of 414.14%. Given Imunon's higher possible upside, analysts clearly believe Imunon is more favorable than Athira Pharma.

Imunon's return on equity of -341.23% beat Athira Pharma's return on equity.